Article Text
Statistics from Altmetric.com
We thank Drs Jenkins and Beasley for their comments in the recent editorial regarding tiotropium (SPIRIVA).1 Preceding the Singh et al 2 analysis cited by the authors, Boehringer Ingelheim (BI) had analysed both the tiotropium HandiHaler and Respimat pooled datasets using patient-level data on-treatment as well as including vital status. The results showed a nominally statistically significant reduction for tiotropium HandiHaler and a numerical increase with tiotropium Respimat compared with the respective placebo group for all-cause mortality.
These results are adequately reflected in the local SPIRIVA product information (http://www.medicines.org.uk/EMC/searchresults.aspx?term=spiriva&searchtype=QuickSearch) …
Supplementary materials
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Files in this Data Supplement:
- Data supplement 1 - Online supplement
Linked Articles
- PostScript